文献速递免疫规划卫生政策与健康促进

将带状疱疹疫苗纳入韩国国家免疫规划的成本效果分析

Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea.
PubMed 文献 · Vaccine · 2025-08-27

本研究采用决策树马尔可夫模型,比较韩国国家免疫规划引入重组带状疱疹疫苗(RZV)和带状疱疹减毒活疫苗(ZVL)与自愿接种ZVL的终身成本效果,分析50至75岁人群。结果显示RZV策略对带状疱疹发病率的降低幅度大于ZVL,但ZVL策略更具成本效果,主要因韩国ZVL价格显著低于RZV。

要点

  • 在70岁人群中,自愿接种策略下带状疱疹终身发病率为20.78%,国家免疫规划RZV策略为9.04%,ZVL策略为18.04%。

核心结论

  • 在韩国,国家免疫规划接种RZV较接种ZVL可显著更大程度降低带状疱疹发病率。
  • 国家免疫规划接种ZVL比接种RZV更具成本效果,主要因韩国ZVL价格显著低于RZV。
  • 国家免疫规划疫苗接种政策决策应考虑成本效果、社会需求和财政可持续性等多因素,以确保最佳且可持续的免疫策略。

研究设计与样本

  • 采用决策树马尔可夫模型,估计终身成本和质​​量调整生命年(QALY)。
  • 比较国家免疫规划接种RZV和ZVL与自愿接种ZVL的终身成本效果。
  • 分析50、55、60、65、70和75岁人群。
  • 主要结局指标为从社会视角计算的增量成本效果比(ICER)。
  • 假设国家免疫规划接种率为70%,自愿接种率为10%。

主要发现

  • 在自愿接种策略下,70岁时带状疱疹终身发病率估计为20.78%;国家免疫规划RZV策略为9.04%,国家免疫规划ZVL策略为18.04%。
  • 结果对带状疱疹发病率、国家免疫规划疫苗价格、疫苗效力和疾病相关成本的变化最为敏感。

关键数值与推荐

  • 70岁时带状疱疹终身发病率:自愿接种20.78%,国家免疫规划RZV 9.04%,国家免疫规划ZVL 18.04%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes zoster (HZ) vaccination is not publicly funded in Korea. This study aimed to assess the cost-effectiveness of introducing recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) into Korea's national immunization program (NIP). METHODS: A decision tree Markov model was used to estimate expected costs and quality-adjusted life years (QALYs) by comparing the lifetime cost-effectiveness of NIP vaccination strategies with RZV and ZVL to that of voluntary ZVL vaccination. We analyzed people aged 50, 55, 60, 65, 70, and 75 years. The primary outcome measure was the incremental cost-effectiveness ratio (ICER) from a societal perspective. We assumed inoculation rates of 70 % for NIP and 10 % for voluntary vaccination. RESULTS: Under the voluntary vaccination strategy, the lifetime incidence of HZ was estimated at 20.78 % at the age of 70 years, whereas it was 9.04 % for the NIP with RZV and 18.04 % for the NIP with ZVL. The ICERs for the NIP RZV strategy ranged from 15.38 to 27.87 million Korean Won (KRW) per QALY compared to voluntary vaccination, whereas the ICERs for the NIP ZVL ranged from -8.42 to 14.39 million KRW per QALY. The results were most sensitive to changes in the HZ incidence, NIP vaccine price, vaccine efficacy, and illness-related cost. CONCLUSION: NIP vaccination with RZV yields a significantly greater reduction in the incidence of HZ compared to vaccination with ZVL in Korea. However, NIP vaccination with ZVL is more cost-effective than vaccination with RZV, primarily due to the significantly lower cost of ZVL compared to RZV in Korea. Decisions regarding NIP vaccination policies should consider multiple factors, including cost-effectiveness, social needs, and financial sustainability, to ensure an optimal and sustainable immunization strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cheong C, Choi WS, An JE, et al. Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea. Vaccine. 2025. PMID: 40882264. doi:10.1016/j.vaccine.2025.127648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。